The Science of More Options
November is Lung Cancer Awareness Month
Hear from the doctors, researchers, and patients behind the newest treatment options for lung cancer.
And as always, spreading awareness that anyone with lungs can get lung cancer. Especially to Veterans you know!
Recently diagnosed with lung cancer?
Learn more about your lung cancer diagnosis. What questions should you be asking? What are the most important next steps? Know that you have options and remember that knowledge is power.
Meet the Researchers
View All-
-
Jonathan Villena-Vargas, MD
Thoracic Surgeon
Characterizing T cell PD-1 response in the tumor-draining lymph nodes of early-stage NSCLC patients
-
Kellie Smith, PhD
Leading an immunology lab in transformative cancer research
Immunotherapy in Early Stage Lung Cancer
Together we can make a lasting impact
Your support is vital to our mission of funding transformative science and improving survivorship.
Stay Connected
Hope, Research, and Impact in Your Inbox
Join our community and receive monthly updates on inspiring stories, groundbreaking research, and the early career researchers you’re helping to support. Sign up now to be part of the lung cancer fight!
-
Research is HOPE. Research will hopefully have me sitting here in #GiveMe20. Give me 20 years post-diagnosis.
Brandi Bryant, living with lung cancer
-
Your generosity is shaping future leaders in lung cancer research.
Kim Norris, Co-Founder and President
-
There is such tremendous hope for all patients with lung cancer right now.
Dr. Christine Lovly, LCFA Young Investigator
Word of the Day
EXON 21 L858R
EXON 21 L858R is a specific mutation in the EGFR gene that can occur in non-small cell lung cancer (NSCLC). It is one of the most common EGFR mutations and can be targeted with specific therapies known as EGFR inhibitors.